Dissociation of blood pressure and resistance artery structure: Potential clinical implications

Basic and Clinical Pharmacology and Toxicology

Volumn 110, Issue 1, 2012, Pages 73-79

  Christensen, Kent L ^a,b   Buus, Niels H ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTERY RESISTANCE; BLOOD PRESSURE; CARDIOVASCULAR PARAMETERS; CORONARY ARTERY BLOOD FLOW; ESSENTIAL HYPERTENSION; FOREARM BLOOD FLOW; HEMODYNAMICS; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; SMALL ARTERY STRUCTURAL CHANGE; VASCULAR RESISTANCE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIES; ARTERIOLES; BIOLOGICAL MARKERS; BLOOD PRESSURE; HEART FAILURE; HUMANS; HYPERTENSION; MICROCIRCULATION; PROGNOSIS; RENAL INSUFFICIENCY; RISK FACTORS; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATION;

ANGINA;

EID: 83455256339     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00799.x     Document Type: Short Survey

References (59)

1. Chobanian AV. Shattuck lecture. The hypertension paradox - more uncontrolled disease despite improved therapy. N Engl J Med 2009;361:878-87.
2. Zanchetti A, Hansson L, Dahlöf B, Elmfeldt D, Kjeldsen S, Kolloch R et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens 2001;19:1149-59.
3. Almgren T, Persson B, Wilhelmsen L, Rosengren A, Anderson OK. Stroke and coronary heart disease in treated hypertension - a prospective cohort study over three decades. J Intern Med 2005;257:496-502.
4. Eftekhari A, Mathiassen ON, Buus NH, Gotzsche O, Mulvany MJ, Christensen KL. Disproportionally impaired microvascular structure in essential hypertension. J Hypertens 2011;29:896-905.
5. Mundal R, Kjeldsen SE, Sandvik L, Erikssen G, Thaulow E, Erikssen J. Exercise blood pressure predicts mortality from myocardial infarction. Hypertension 1996;27:324-9.
6. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich M, Schmieder RE et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903-9.
7. Mulvany MJ. Abnormalities of the resistance vasculature in hypertension: correction by vasodilator therapy. Pharmacol Rep 2005;57(Suppl):144-50.
8. Rizzoni D, De Ciuceis C, Porteri E, Paiardi S, Boari GE, Mortini P et al. Altered structure of small cerebral arteries in patients with essential hypertension. J Hypertens 2009;27:838-45.
9. Short D. Morphology of the intestinal arterioles in chronic human hypertension. Br Heart J 1966;28:184-92.
10. Vogt M, Motz WH, Schwartzkopf B, Strauer BE. Pathophysiology and clinical aspects of hypertensive hypertrophy. Eur Heart J 1993;14(Suppl D):2-7.
11. Sivertsson R, Andersson O, Hansson L. Blood pressure reduction and vascular adaptation in the calf. A study on long-term effects of treatment with mefruside or atenolol. Acta Med Scand 1979;205:477-82.
12. Folkow B, Grimby G, thulesius O. Adaptive structural changes of the vascular walls in hypertension and their relation to the control of the peripheral resistance. Acta Physiol Scand 1957;44:255-72.
13. Strauer BE. Ventricular function and coronary haemodynamics in hypertensive heart disease. Am J Cardiol 1979;44:999-1006.
14. Lund-Johansen P. Twenty-year follow-up of hemodynamics in essential hypertension during rest and exercise. Hypertension 1991;18:III54-61.
15. Vogt M, Motz W, Schwartzkopff B, Strauer BE. Coronary microangiopathy and cardiac hypertrophy. Eur Heart J 1990;11(Suppl B):133-8.
16. Vogt M, Motz W, Schwartzkopff B, Strauer BE. Coronary haemodynamics in hypertensive heart disease. Eur Heart J 1992;13(Suppl D):D44-9.
17. Antonios TF, Singer DRJ, Markandu ND, Mortimer PS, MacGregor GA. Structural skin capillary rarefaction in essential hypertension. Hypertension 1999;33:998-1001.
18. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
19. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic hypertension in Europe investigators. JAMA 1999;282:539-46.
20. Sakuma M, Imai Y, Nagai K, Watanabe N, Sakuma H, Minami N et al. Reproducibility of home blood pressure measurements of a 1-year period. Am J Hypertens 1997;10:798-803.
21. Hansen TW, Kikuya M, Thijs L, Björklund-Bodegård K, Kuznetsova T, Ohkubo T et al. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7, 030 individuals. J Hypertens 2007;25: 1554-64.
22. Law MR, Wald NJ, Morris JR, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomized trials. BMJ 2003;326:1427.
23. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24: 987-1003.
24. Mancia G, de Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.
25. Ibsen H, Olsen MH, Wachtell K, Borch-Johansen K, Lindholm LH, Mogensen CE et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients. The LIFE study. Hypertension 2005;45:198-202.
26. Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlöf B, Devereux RB et al. Reductions in electrographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006;24:775-81.
27. Girerd Z, Laurent S, Pannier B, Asmar R, Safar M. Arterial distensibility and left ventricular hypertrophy in patients with sustained essential hypertension. Am Heart J 1991;122:1210-4.
28. Sehestedt T, Olsen MH. Subclinical organ damage and cardiovascular risk prediction. Blood Press 2010;19:132-9.
29. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982;62:347-504.
30. Mulvany MJ. Small artery remodelling in hypertension: causes, consequences and therapeutic implications. Med Biol Eng Comput 2008;46:461-7.
31. Park JB, Schiffrin EL. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 2001;19:921-30.
32. Nielsen S, Eftekhari A, Mathiassen ON, Christensen KL. Albuminuria: a measure of generalized vascular damage?. J Hypertens 2010;28(e-Suppl A):e180.
33. Rizzoni D, Porteri E, Boari GE, De Ciuceis C, Sleiman I, Muiesan ML et al. Prognostic significance of small-artery structure in hypertension. Circulation 2003;108:2230-5.
34. Mathiassen ON, Buus NH, Sihm I, Thybo NK, Mørn B, Schroeder AP et al. Small artery structure is an independent predictor of cardiovascular events in essential hypertension. J Hypertens 2007;25:1021-6.
35. De Ciuceis C, Porteri E, Rizzoni D, Rizzardi N, Paiardi S, Boari GE et al. Structural alterations of subcutaneous small arteries may predict major cardiovascular events in hypertensive patients. Am J Hypertens 2007;20:846-52.
36. Praestholm MN, Mathiassen ON, Fenger-Grøn M, Buus NH, Sihm I, Thybo NK et al. Small artery structure during long-term therapy is an independent predictor of cardiovascular events in uncomplicated essential hypertension. J Am Coll Cardiol 2009;53:A211.
37. Schmieder RE, Schlaich MP, Klingbeil AU. Reversal of left ventricular hypertrophy in essential hypertension. A metaanalysis of randomized, double blind studies. JAMA 1996;275:1507-13.
38. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995;25:474-81.
39. Sihm I, Schroeder AP, Aalkjaer C, Holm M, Morn B, Mulvany M et al. Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril. Blood Press 1995;4:241-8.
40. Schiffrin EL, Deng LY, Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker. Am J Hypertens 1995;8:229-36.
41. Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens 2002;20:71-8.
42. Schiffrin EL, Pu Q, Park JB. Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients. Am J Hypertens 2002;15:105-10.
43. Sihm I, Schroeder AP, Aalkjaer C, Mulvany MJ, Thygesen K, Lederballe O. Effect of antihypertensive treatment on cardiac and subcutaneous artery structure: a comparison between calcium channel blocker and thiazide-based regimens. Am J Hypertens 1998;11:263-71.
44. Agabiti-Rosei E, Heagerty AM, Rizzoni D. Effects of antihypertensive treatment on small artery remodelling. J Hypertens 2009;27:1107-14.
45. Mathiassen ON, Buus NH, Larsen ML, Mulvany MJ, Christensen KL. Small artery structure adapts to vasodilatation rather than to blood pressure during antihypertensive treatment. J Hypertens 2007;25:1027-34.
46. Buus NH, Bøttcher M, Jorgensen CG, Christensen KL, Thygesen K, Nielsen TT et al. Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or beta-blockade in patients with essential hypertension. Hypertension 2004;44: 465-70.
47. Christensen KL, Mulvany MJ. Vasodilation, not hypotension, improves resistance vessel design during treatment of essential hypertension. A literature survey. J Hypertens 2001;19:1001-6.
48. Aalkjaer C, Heagerty AM, Petersen KK, Swales JD, Mulvany MJ. Evidence for increased media thickness, increased neuronal amine uptake, and depressed excitation-contraction coupling in isolated resistance vessels from essential hypertensives. Circ Res 1987;61:181-6.
49. Mathiassen ON, Olsen HW, Larsen ML, Mulvany MJ, Buus NH, Christensen KL. Forearm plethysmography in the assessment of vascular resistance: new methodological insights. Acta Physiol 2006;188:91-101.
50. Folkow B, Grimby G, Thulesius O. Adaptive structural changes of the vascular walls in hypertension and their relation to the control of the peripheral resistance. Acta Physiol Scand 1958;44: 255-72.
51. Lund-Johansen P. Central haemodynamics in essential hypertension at rest and during exercise: a 20-year follow-up study. J Hypertens 1989;7(Suppl.):S52-5.
52. Buus NH, Bøttcher M, Hermansen F, Sander M, Nielsen TT, Mulvany MJ. Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation 2001;104:2305-10.
53. Kozàkovà M, Palombo C, Pratali L, Pittella G, Galetta F, L'Abbate A. Mechanisms of coronary flow reserve impairment in human hypertension. An integrated approach by transthoracic and transesophageal echocardiography. Hypertension 1997;29: 551-9.
54. Dimitrow PP. Transthoracic Doppler echocardiography - noninvasive diagnostic window for coronary flow reserve assessment. Cardiovasc Ultrasound 2003;1:4.
55. Abdelmoneim SS, Bernier M, Dhoble A, Moir S, Hagen ME, Ness SA et al. Diagnostic accuracy of contrast echocardiography during adenosine stress for detection of abnormal myocardial perfusion: a prospective comparison with technetium-99m sestamibi single-photon emission computed tomography. Heart Vessels 2010;25:121-30.
56. Shantsila A, Dwivedi G, Shantsila E, Butt M, Beevers DG, Lip GY. Persistent macrovascular and microvascular dysfunction in patients with malignant hypertension. Hypertension 2011;57: 490-6.
57. Parodi O, Neglia D, Palombo C, Sambuceti G, Giorgetti A, Marabotti C et al. Comparative effects of enalapril and verapamil on myocardial blood flow in systemic hypertension. Circulation 1997;96:864-73.
58. Kawecka-Jaszcz K, Czarnecka D, Olszanecka A, Klecha A, Kwiecień-Sobstel A, Stolarz-Skrzypek K et al. Myocardial perfusion in hypertensive patients with normal coronary angiograms. J Hypertens 2008;26:1986-97.
59. Harazny JM, Ritt M, Baleanu D, Ott C, Heckmann J, Schlaich MP et al. Increased wall:lumen ratio of retinal arterioles in male patients with a history of a cerebrovascular event. Hypertension 2007;50:623-9.